drugset / Trial / NCT04081363

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

NCT04081363

NaSingle-groupOpen-labelTreatment

Summary

With the pharmacokinetics (PK) of centanafadine currently being evaluated in adults. The PK of extended-release centanafadine may differ in children compared to adults due to physiological differences in the gastrointestinal tract. The information in this trial will support pediatric dose selection in future trials.

Timeline

Start
2019-10-07
Primary completion
2019-12-21
Completion
2019-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule 55 mg Oral